Pavone P, Cho SY, Praticò AD, et al. Ptosis in childhood: a clinical sign of several disorders: case series reports and literature review. Medicine (Baltimore). 2018;97(36):e12124
Alsuhaibani A. Blepharoptosis. American Academy of Ophthalmology website. https://eyewiki.aao.org/Blepharoptosis. Updated May 2019. Accessed September 9, 2019.
Latting MW, Huggins AB, Marx DP, et al. Clinical evaluation of blepharoptosis: distinguishing age-related ptosis from masquerade conditions. Semin Plast Surg. 2017;31:5-16.
Koka K, Patel BC. Ptosis. The National Center for Biotechnology Information website. https://www.ncbi.nlm.nih.gov/books/NBK539828/. Accessed September 9, 2019.
Lim JM, Hou JH, Singa RM, et alP. Relative incidence of blepharoptosis subtypes in an oculoplastics practice at a tertiary care center. Orbit. 2013;32:231-234.
Beard C. The surgical treatment of blepharoptosis: a quantitative approach. Trans Am Ophthalmol Soc. 1966;64:401-487.
Grob D, Brunner N, Namba T, et al. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37:141-149.
King M. Management of Ptosis. J Clin Aesthet Dermatol. 2016;9:E1-E4.
Davagnanam I, Fraser CL, Miszkiel K, et al. Adult Horner's syndrome: a combined clinical, pharmacological, and imaging algorithm. Eye (Lond). 2013;27:291-298.
Yom KH, Ricca AM, Ko AC. Phenylephrine response in upper eyelid ptosis. University of Iowa Health Care, Department of Ophthalmology and Visual Sciences. EyeRounds website. http://webeye.ophth.uiowa.edu/eyeforum/atlas/pages/phenylephrine-response-upper-eyelid-ptosis.htm. Accessed August 16, 2019.
Barsegian A, Botwinick A, Reddy HS. The phenylephrine test revisited. Ophthalmic Plast Reconstr Surg 2018;34:151-154.
Morales J, Brown SM, Abdul-Rahim AS, et al. Ocular effects of apraclonidine in Horner syndrome. Arch Ophthalmol. 2000 Jul;118:951-954.
Yazici B, Beden U. Use of 0.5% apraclonidine solution in evaluation of blepharoptosis. Ophthalmic Plast Reconstr Surg. 2008;24:299-301.
Steinsapir KD, Groth MJ, Boxrud CA. Persistence of upper blepharoptosis after cosmetic botulinum toxin type A. Dermatol Surg. 2015 Jul;41:833-840.
Mustak H, Rafaelof M, Goldberg RA, et al. Use of botulinum toxin for the correction of mild ptosis. J Clin Aesthet Dermatol. 2018;11:49-51.
Fagien S. Temporary management of upper lid ptosis, lid malposition, and eyelid fissure asymmetry with botulinum toxin type A. Plast Reconstr Surg. 2004;114:1892-1902.
Jubbal KT, Kania K, Braun TL, et al. Pediatric blepharoptosis. Semin Plast Surg. 2017;31:58-64.
SooHoo JR, Davies BW, Allard FD, et al. Congenital ptosis. Surv Ophthalmol. 2014;59:483-492.
Vrcek I, Hogan RN, Rossen J, et al. Conjunctiva-sparing posterior ptosis surgery: a novel approach. Ophthalmic Plast Reconstr Surg. 2016;32:366-370.
ClinicalTrials.gov. Study of the safety and efficacy of RVL-1201 in the treatment of acquired blepharoptosis https://clinicaltrials.gov/ct2/show/NCT02436759. Accessed September 9, 2019.
Slonim C, Silverberg M, Butler B, et al. RVL-1201 ophthalmic solution improves the superior field of vision in subjects with upper eyelid ptosis. Presented at: the Association for Research in Vision and Ophthalmology 2017 Annual Meeting; May 7-11, 2017; Baltimore, MD. Abstract.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Ivan Vrcek, MD

Associate Adjunct Professor of Ophthalmology and Oculoplastic Surgery
Texas A&M Medical School, Dallas Campus
Clinical Assistant Professor of Ophthalmology and Oculoplastic Surgery
UT Southwestern Medical Center
Department of Ophthalmology
Private Practice
Texas Eye Plastics
Dallas, Texas

Disclosures

Disclosure: Ivan Vrcek, MD, has disclosed no relevant financial relationships.

Editors

Pakinam Aboulsaoud, PharmD

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Pakinam Aboulsaoud, PharmD, has disclosed no relevant financial relationships.

Amy Hellem

Freelance Medical Writer/Scientific Director, Trabuco Canyon, California

Disclosures

Disclosure: Amy Hellem has disclosed no relevant financial relationships.

CME Reviewer

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME / ABIM MOC

Assessing the Clinical Recognition and Management of Blepharoptosis

Authors: Ivan Vrcek, MD
CME / ABIM MOC Released: 9/18/2019
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 9/18/2020

Start Activity

Target Audience and Goal Statement

This activity is intended for ophthalmologists, optometrists, dermatologists, primary care physicians, and other clinicians who care for patients with blepharoptosis.

The goal of this activity is to assess physician knowledge of current and emerging treatment options for the management of patients with blepharoptosis.

Upon completion of this activity, participants will:

Have increased knowledge regarding
- Investigational therapies being studied for the management of blepharoptosis
Self-assess learning needs related to
- Currently available therapies for the management of blepharoptosis

Disclosures

Faculty

Ivan Vrcek, MD

Associate Adjunct Professor of Ophthalmology and Oculoplastic Surgery
Texas A&M Medical School, Dallas Campus
Clinical Assistant Professor of Ophthalmology and Oculoplastic Surgery
UT Southwestern Medical Center
Department of Ophthalmology
Private Practice
Texas Eye Plastics
Dallas, Texas

Disclosures

Disclosure: Ivan Vrcek, MD, has disclosed no relevant financial relationships.

Editors

Pakinam Aboulsaoud, PharmD

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Pakinam Aboulsaoud, PharmD, has disclosed no relevant financial relationships.

Amy Hellem

Freelance Medical Writer/Scientific Director, Trabuco Canyon, California

Disclosures

Disclosure: Amy Hellem has disclosed no relevant financial relationships.

CME Reviewer

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

processing....

Abbreviations

CN3 = cranial nerve 3
HS = Horner syndrome
LF = levator function
LPFT = Leicester Peripheral Field Test
MG = myasthenia gravis
MRD = margin to reflex distance
NSAID = non-steroidal anti-inflammatory drug

« Return to: Assessing the Clinical Recognition and Management of Blepharoptosis

CME / ABIM MOC Information

Print
Like Tweet

References

Faculty and Disclosures

Faculty

Ivan Vrcek, MD

Editors

Pakinam Aboulsaoud, PharmD

Amy Hellem

CME Reviewer

Esther Nyarko, PharmD

Peer Reviewer

CME / ABIM MOC

Assessing the Clinical Recognition and Management of Blepharoptosis

Target Audience and Goal Statement

Disclosures

Faculty

Ivan Vrcek, MD

Editors

Pakinam Aboulsaoud, PharmD

Amy Hellem

CME Reviewer

Esther Nyarko, PharmD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Assessing the Clinical Recognition and Management of Blepharoptosis

Abbreviations